Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks.

Abstract

Naproxen was compared with placebo in a double-blind, crossover trial in classic and common migraine. The trial was terminated at a fixed date; 37 patients had entered, 5 of whom were excluded. Naproxen was given as 750 mg at the first symptom of the attack, a total of 1250 mg per 24 h was allowed. Patients were followed for six attacks or three months in each phase, whichever came first. The severity of the headache was significantly less with naproxen in the first 2 h of the attack (p = 0.047), whereas there was no difference when the whole attack was considered. Significantly more patients preferred naproxen (p = 0.042). Side effects occurred in five patients, causing withdrawal of one patient while on naproxen.

• Authors: P G Andersson, H H Hinge, O Johansen, C U Andersen, A Lademann, P C Gøtzsche
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 9 Issue 1 Pg. 29-32 (Mar 1989) ISSN: 0333-1024 [Print] England
• PMID: 2650879 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Placebos
• Naproxen

Topics

• Acute Disease
• Clinical Trials as Topic
• Double-Blind Method
• Humans
• Migraine Disorders (drug therapy, physiopathology)
• Naproxen (adverse effects, therapeutic use)
• Placebos
• Stomach Diseases (chemically induced)